Log in

Relevant bibliographies by topics / DEVDC / Journal articles

Journal articles on the topic 'DEVDC'

To see the other types of publications on this topic, follow the link: DEVDC.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'DEVDC.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Foroughipour, Mohsen, Zeinab Nikbin, Maryam Sahebari, Masoud Pezeshki Rad, and Ali Shoeibi. "Devic Syndrome." Journal of Clinical Rheumatology 18, no. 8 (December 2012): 419–21. http://dx.doi.org/10.1097/rhu.0b013e318277a9de.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Papeix, Caroline. "Maladie de Devic." La Presse Médicale 35, no. 11 (November 2006): 1703–6. http://dx.doi.org/10.1016/s0755-4982(06)74884-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Berglöff, J., and G. Ranner. "Neuromyelitis optica Devic." Spektrum der Augenheilkunde 8, no. 3 (June 1994): 142–46. http://dx.doi.org/10.1007/bf03163923.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Duhin, E., M. Giroux, A. Etxeberria, E. Boyle, H. Zephir, X. Leleu, and P. Vermersch. "Un « Devic » indolent." Revue Neurologique 169 (April 2013): A103—A104. http://dx.doi.org/10.1016/j.neurol.2013.01.248.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Miyazawa, Isabelle, Kazuo Fujihara, and Yasuto Itoyama. "Eugène Devic (1858-1930)." Journal of Neurology 249, no. 3 (March 1, 2002): 351–52. http://dx.doi.org/10.1007/s004150200020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ueda, Kyoko, Noriko Nishimura, Yuko Mishima, Hideaki Nitta, Yoshiharu Kusano, Masahiro Yokoyama, Naoko Tsuyama, et al. "RT-DeVIC Therapy Is Effective for Localized NK/T Cell Lymphoma Patiens." Blood 124, no. 21 (December 6, 2014): 1702. http://dx.doi.org/10.1182/blood.v124.21.1702.1702.

Full text

Abstract:

Abstract BACKGROUNDS: Extranodal natural killer (NK) /T cell lymphoma, nasal type is much common in East Asia than in Western countries. CHOP therapy is not effective for NK/T cell lymphoma because of the drug resistance induced by P glycoprotein. Yamaguchi et al reported the effectiveness of concurrent radiotherapy and DeVIC (RT-DeVIC) therapy for localized nasal NK/T cell lymphoma. Nowadays, RT-DeVIC therapy is recognized as a standard treatment. So far, we have limited information about this treatment because NK/T cell lymphoma is rare phenotype. PATIENTS AND METHODS: We reviewed retrospectively the patients with localized NK/T cell lymphoma treated with RT-DeVIC therapy. Radiation therapy was administered for a total dose of 50 Gy. Concurrently, chemotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (DeVIC) was performed up to 3 cycles. The primary objectives of this analysis were to evaluate the response rates and progression free survival (PFS) and overall survival (OS). RESULTS: A total of 20 patients who diagnosed as nasal NK/T cell lymphoma between April 2007 and October 2012 were analyzed. Sixteen patients were stage 1E and 4 were Stage 2E. As the NK/T cell lymphoma prognostic index, 6 patients were group 1, 10 were group 2, 3 were group 3, and 1 was group 4. Seventeen patients completed 3 cycles of DeVIC therapy and 19 patients completed planned radiation therapy. Overall response rate (ORR) was 75% and CR rate was 70% in the entire patients. Local control was 90%. Half of the patients who reached CR showed long time survival without disease progression. On the other hand, 7 of 14 patients relapsed after CR, and all 5 patients experienced systemic failure. The sites of relapse were paranasal sinuses (n=2), skin (n=3), brain (n=1), testis (n=1). Among them, one patient reached 2nd CR. However, 5 patients were not eligible for salvage chemotherapy, because lymphoma progressed rapidly and their general condition became worse. Six patients did not reach CR after RT-DeVIC therapy. Five of them experienced systemic relapse and median survival of them was only 8 months. The median follow up time was 17.6 months (range 2 – 77.9 months). Median overall survival was not reached and median progression free survival was 14.6 months. Risk factors predicted of OS or PFS were not clear. All entire patients experienced grade 3 or 4 neutropenia. Mucositis was common non-hematological toxicity and it was the major cause of grade 3 or 4 appetite loss. Only one patient discontinued RT-DeVIC due to grade 3 mucositis, grade 3 dermatitis and septic shock. CONCLUSION: We reviewed treatment outcomes of 20 cases of RT-DeVIC therapy. In this analysis, the majority of relapsed or refractory cases showed systemic disease and the prognosis of these patients were poor. However, RT-DeVIC therapy showed excellent local control and response rates which were similar to the prior study. The effectiveness of RT-DeVIC therapy for patients with NK/T cell lymphoma was reconfirmed. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

7

Bibiano, Alana Maiara Brito, Jaqueline Silva Veloso, and Walderi Monteiro da Silva Junior. "Capacidade funcional na doença de Devic." Revista Neurociências 23, no. 4 (December 31, 2015): 603–8. http://dx.doi.org/10.34024/rnc.2015.v23.7993.

Full text

Abstract:

Introdução. A Doença de Devic é uma doença inflamatória, desmielinizante, imunomediada e necrotizante do sistema nervoso central, caracterizada por afetar o nervo óptico e a medula espinhal. Objetivo. Avaliar a capacidade funcional de uma paciente com Doença de Devic submetida a tratamento clínico e fisioterapêutico. Método. Relato de caso do tipo descritivo, retrospectivo, de abordagem quantitativa, de uma paciente com Doença de Devic. Para avaliação da funcionalidade aplicou-se o questionário Medida de Independência Funcional (MIF) na admissão e alta hospitalar. Na admissão foi constatado o valor de MIF =38, o qual representa total dependência da paciente para suas atividades cotidianas, e na alta a paciente evoluiu seu quadro funcional para independência parcial de suas atividades diárias, representando um valor de MIF=102. Conclusão. A paciente com Doença de Devic obteve melhora na capacidade funcional na alta hospitalar.

APA, Harvard, Vancouver, ISO, and other styles

8

Pinzón, Alfredo, Tatiana Echeverry, and Aida Bibiana Rodríguez. "Neuromielitis óptica (enfermedad de Devic)." Acta Médica Colombiana 35, no. 1 (November 29, 2019): 21–25. http://dx.doi.org/10.36104/amc.2010.1579.

Full text

Abstract:

Presentamos el caso de una mujer joven inicialmente tratada por esclerosis múltiple, quien presentó recurrencia con compromiso ocular severo. La enfermedad de Devic es un desorden desmielinizante que se presenta como una mielitis transversa asociada con neuritis óptica, típicamente bilateral. El principal diagnóstico diferencial es justamente la esclerosis múltiple

APA, Harvard, Vancouver, ISO, and other styles

9

Silva, Alexandre R., Sonja V. T. Barros, Newra Tellechea Rotta, Lygia Ohlweiler, Isa Stone, and Letícia R. Mello. "Devic disease: a case report." Jornal de Pediatria 77, no. 6 (November 15, 2001): 522–4. http://dx.doi.org/10.2223/jped.356.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Joshi, Ajit, Milind Suryawanshi, and Satyanarayanamurthy Ayyori. "Neuromyelitis optica: Devic′s disease." Journal of Clinical Ophthalmology and Research 3, no. 1 (2015): 32. http://dx.doi.org/10.4103/2320-3897.149371.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Cross, Shelley Ann. "Rethinking Neuromyelitis Optica (Devic Disease)." Journal of Neuro-Ophthalmology 27, no. 1 (March 2007): 57–60. http://dx.doi.org/10.1097/wno.0b013e3180334d27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Sofat, N., and P. J. Venables. "Is Sjogren myelopathy Devic disease?" Annals of the Rheumatic Diseases 67, no. 5 (August 17, 2007): 730–31. http://dx.doi.org/10.1136/ard.2007.077883.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Bourokba, Samia, Amina Diaf, Lhaj Khengaoui, and Nadia Toubal. "Neuromyélite optique de Devic familiale." Revue Neurologique 176 (September 2020): S14—S15. http://dx.doi.org/10.1016/j.neurol.2020.01.083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Hamzy, R., A. Moussair, H. Lamari, D. Lahbil, A. El Kettani, L. Rais, and K. Zaghloul. "579 La neuromyélite de Devic." Journal Français d'Ophtalmologie 30 (April 2007): 2S316. http://dx.doi.org/10.1016/s0181-5512(07)80392-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Perwaiz, Muhammad K., Fadi Hammoudeh, and Francis Schmidt. "Devic Syndrome: A Diagnostic Dilemma." Journal of the National Medical Association 103, no. 2 (February 2011): 176–78. http://dx.doi.org/10.1016/s0027-9684(15)30269-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Chalumeau-Lemoine, Ludivine, Fabrice Chretien, Anne Gaëlle Si Larbi, Pierre Brugieres, Françoise Gray, Christian Brun-Buisson, and Alain Creange. "Devic Disease With Brainstem Lesions." Archives of Neurology 63, no. 4 (April 1, 2006): 591. http://dx.doi.org/10.1001/archneur.63.4.591.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Sun, Lei, Christopher H. Hendon, Mikael A. Minier, Aron Walsh, and Mircea Dincă. "Million-Fold Electrical Conductivity Enhancement in Fe2(DEBDC) versus Mn2(DEBDC) (E = S, O)." Journal of the American Chemical Society 137, no. 19 (May 6, 2015): 6164–67. http://dx.doi.org/10.1021/jacs.5b02897.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Stott, Ian, Anupama Murthy, Alex Robinson, Norman W. Thomas, and Jeffrey R. Fry. "Low-dose diethyldithiocarbamate attenuates the hepatotoxicity of 1,3-Dichloro-2-propanol and selectively inhibits CYP2E1 activity in the rat." Human & Experimental Toxicology 16, no. 5 (May 1997): 262–66. http://dx.doi.org/10.1177/096032719701600505.

Full text

Abstract:

The effect of low doses of diethyldithiocarbamate (DEDC) on hepatic cytochrome P450-dependent enzyme activity and 1,3-dichloro-2-propanol (DCP) hepatotoxicity in the rat have been investigated. DEDC at a dose of 5 mg/kg selectively inhibited enzyme markers for CYP2E1 activity, and provided substantial protection against DCP hepato toxicity. At a higher dose (25 mg/kg), DEDC also inhibited an enzyme marker for CYP1A2 activity and provided complete protection against DCP hepatotoxicity. It is concluded: (a) that DEDC at a dose of 5 mg/kg is a selective CYP2E1 inhibitor in the rat in vivo; and (b) that DCP hepatotoxicity is mediated principally by CYP2E1, with a possible contribution from CYP1A2.

APA, Harvard, Vancouver, ISO, and other styles

19

Ota, H., S. Igarashi, and T. Tanaka. "Improved fertility through superoxide removal by Toki-shakuyaku-san in mice - a preliminary study." Reproduction, Fertility and Development 11, no. 8 (1999): 451. http://dx.doi.org/10.1071/rd00001.

Full text

Abstract:

The effect of a superoxide dismutase inhibitor on pregnancy rate and fetal survival, and the effect of concomitant treatment with Toki-shakuyaku-san, was studied. Twelve week-old IV CS female mice were given diethyldithiocarbamate (DEDC; 0.9, 9, 45, and 225 mg kg–1) intraperitioneally, from Day 3 to Day 5 of pregnancy, every 12 h, for a total of six times. Two additional groups received both 45 mg kg–1 DEDC and Toki-shakuyaku-san (50 or 200 mg/100 mL), by water bottle, from 12 h before to 12 h after DEDC administration. For each group, the pregnancy rate, the number of surviving fetuses, and the number of resorbed fetuses was calculated. Pregnancy rates were 95.5, 81.8, 54.5 and 0%, respectively, in the DEDC groups and were 100% in the control group. The fetal resorption rate was 0.9 in the control group, and 1.0, 1.7, and 2.3, respectively, in the 0.9, 9, 45 mg kg–1 DEDC groups. Administration of 200 mg Toki-shakuyaku-san significantly (P<0.05) improved the pregnancy rate to 81.8%, and improved the degree of reduced intercellular interactions and insufficient decidual reactions found on Day 5 in the endometrium of the DEDC groups. Toki-shakuyaku-san reduces the adverse effects of excess superoxides on the endometrium during implantation.

APA, Harvard, Vancouver, ISO, and other styles

20

Aimoto, Yasuharu, Kazunori Ito, Fumio Moriwaka, Kunio Tashiro, and Kazuhiro Abe. "Demyelinating Peripheral Neuropathy in Devic Disease." Psychiatry and Clinical Neurosciences 45, no. 4 (December 1991): 861–64. http://dx.doi.org/10.1111/j.1440-1819.1991.tb00525.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Ghosh, Joydeep, and Jagabandhu Ghosh. "Can Devic Disease Involve Peripheral Nerves?" Journal of Pediatric Neurology 13, no. 03 (August 7, 2015): 139–42. http://dx.doi.org/10.1055/s-0035-1556834.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Schreiber, Adam L., Guy W. Fried, Christopher S. Formal, and Bryan X. DeSouza. "Rehabilitation of Neuromyelitis Optica (Devic Syndrome)." American Journal of Physical Medicine & Rehabilitation 87, no. 2 (February 2008): 144–48. http://dx.doi.org/10.1097/phm.0b013e31815b5e1a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Rose-John, S., and R. Gold. "Devic disease: Translational medicine at work." Neurology 82, no. 15 (March 14, 2014): 1294–95. http://dx.doi.org/10.1212/wnl.0000000000000322.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Nicolas, P., and R. Marignier. "Neuromielite ottica acuta (malattia di Devic)." EMC - Neurologia 17, no. 1 (February 2017): 1–13. http://dx.doi.org/10.1016/s1634-7072(16)81775-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Iglesias Rodríguez, Antonio, Diana Gil, José Félix Restrepo, and Antonio Iglesias Gamarra. "Historia de la enfermedad de Devic." Revista Colombiana de Reumatología 18, no. 4 (December 2011): 271–84. http://dx.doi.org/10.1016/s0121-8123(11)70043-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Vetrugno, Roberto, Roberto D'Angelo, Maria Alessandria, Marghertia Fabbri, Rocco Liguori, Pasquale Montagna, Sergio Stecchi, and Mario Mascalchi. "Axial myoclonus in devic neuromyelitis optica." Movement Disorders 24, no. 11 (August 15, 2009): 1708–9. http://dx.doi.org/10.1002/mds.22654.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Pique, J., P. Nicolas, and R. Marignier. "Neuromielite ottica acuta (malattia di Devic)." EMC - Neurologia 22, no. 4 (December 2022): 1–11. http://dx.doi.org/10.1016/s1634-7072(22)47095-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Bibiano, Alana, Jaqueline Veloso, and Walderi Silva Junior. "Functional capacity in the Devic disease: case report." Revista Neurociências 23, no. 04 (December 9, 2015): 603–8. http://dx.doi.org/10.4181/rnc.2015.23.04.1049.06p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Puzovic, Ljiljana. "An attempt of reconstruction of the collection of manuscripts of Devic monastery." Prilozi za knjizevnost, jezik, istoriju i folklor, no. 81 (2015): 93–109. http://dx.doi.org/10.2298/pkjif1581093p.

Full text

Abstract:

The Serbian monastery Devic was built in 1434, in Drenica, a hilly region where Kosovo and Metohija meet, and where St. Joannicius of Devic lived his ascetic life, passed away and was buried. This great Serbian hermit, under the patronage of Despot Djuradj Brankovic, built the original church dedicated to the Presentation of the Virgin which gathered the whole monastic family. Probably at the same time the first collection of manuscripts was built, since the elementary liturgical books were needed for the regular liturgical life. Different conserved manuscripts between the 16th and 19th century attest transcription activities in the monastery, and, at the same time, confirm that Devic Monastery was highly estimated among the Orthodox Christians. First information about the literary fund of the monastery originate in the mid-19th century when many researchers and antique lovers visited the monastery. Testimonies about the scope and content of the Devic collection of manuscripts are quite contradictory, however we are going to try to determine in this paper which manuscripts were undoubtedly in the collection with particular attention to the ones written in the monastery. Despite very poor conditions this collection survived until the 20th century. For safety reasons one part of the collection, which was transferred in the National Library of Serbia, got destroyed during the bombing in April 1941. The rest, which was held in the monastery, was burnt down, including the temple church and the whole monastery complex, by the Albanian Fascists. What remained from the former collection were just a few copies of books which were taken out of the Devic before 1941. The monastery continues to exist till the present day, despite vandalization in 2004.

APA, Harvard, Vancouver, ISO, and other styles

30

Knoblach, Susan M., Daniel A. Alroy, Maria Nikolaeva, Ibolja Cernak, Bogdan A. Stoica, and Alan I. Faden. "Caspase Inhibitor z-DEVD-fmk Attenuates Calpain and Necrotic Cell Death in Vitro and after Traumatic Brain Injury." Journal of Cerebral Blood Flow & Metabolism 24, no. 10 (October 2004): 1119–32. http://dx.doi.org/10.1097/01.wcb.0000138664.17682.32.

Full text

Abstract:

In studies designed to evaluate the therapeutic window for treatment of traumatic brain injury, the caspase 3 inhibitor z-DEVD-fmk improved neurologic function and reduced lesion volumes when administered at 1 but not at 4, 8, or 24 hours after injury. Moreover, neither caspase 3 nor PARP, a caspase 3 substrate, were cleaved in injured, untreated cortex from 1 to 72 hours after injury. Few cortical neurons expressed active caspase 3 or were TUNEL positive from 6 to 24 hours after injury, and TUNEL staining was primarily Type I (necrotic). Nissl staining revealed extensive neuronal necrosis in the injured cortex from 6 to 24 hours after impact. Considered together, these data suggested that z-DEVD-fmk may reduce neuronal necrosis, so we used an in vitro model of necrotic cell death induced by maitotoxin to test this further and explore the potential mechanism(s) involved. Z-DEVD-fmk (1 nM-100 μM) significantly attenuated maitotoxin induced neuronal cell death and markedly reduced expression of the 145 kD calpain-mediated α-spectrin breakdown product after maitotoxin injury. Neither the 120 kD caspase-mediated α-spectrin cleavage product nor cathepsin B were expressed after maitotoxin injury. In a cell free assay, z-DEVD-fmk reduced hydrolysis of casein by purified calpain I. Finally, z-DEVD-fmk reduced expression of the 145 kD calpain-mediated α-spectrin cleavage fragment after traumatic brain injury in vivo. These data suggest that neuroprotection by z-DEVD-fmk may, in part, reflect inhibition of calpain-related necrotic cell death.

APA, Harvard, Vancouver, ISO, and other styles

31

Holl, Hans-Guido, Elisabeth Schorb, Jürgen Finke, Nikolaos Vassiliadis, Benjamin Kasenda, and Gerald Illerhaus. "Ifosphamide and Carboplatin Based (R-DeVIC) Salvage Therapy in Patients with Relapsed/Refractory PCNSL - a Multicentre Retrospective Analysis." Blood 132, Supplement 1 (November 29, 2018): 1705. http://dx.doi.org/10.1182/blood-2018-99-117329.

Full text

Abstract:

Abstract Background Primary central nervous system lymphoma (PCNSL) is rare and aggressive Non-Hodgkin lymphoma of the central nervous system (CNS).High-dose methotrexate (HD-MTX) based chemotherapy is standard first-line treatment in newly diagnosed disease. Although remissions can be achieved in most patients, at least a third relapses and therapeutic options in relapsed/refractory PCNSL (r/r PCNSL) are still limited. Aim of this study was to investigate efficacy and safety in of the R-DeVIC protocol consisting of: rituximab, ifosfamide, dexamethason, carboplatin and etoposide. Methods This was a retrospective study based on routinely collected health data from two sites in Germany (Stuttgart and Freiburg). Patient eligibility criteria were: r/r PCNSL confirmed by local pathology treated with at least one prior therapy. The R-DeVIC protocol was applied according to the following schedule: Rituximab 375 mg/m2/d (d0), dexamethasone 40 mg/d (d1-3), etoposide 100 mg/m2/d (d1-3), ifosfamide 1500 mg/m2/d (d1-3), carboplatin 300 mg/m2/ (d1) and repeated after 21 days. Feasibility endpoints included: toxicity, dose density, and treatment related death. Efficacy endpoints included: response as evaluated on brain MRI, progression free survival (PFS) and overall survival (OS). We used descriptive statistics for summarizing patient characteristics and outcomes; including the Kaplan-Meier estimator to plot time-to-event endpoints. Results We identified 19 eligible patients with r/r PCNSL being treated with R-DeVIC between 2010 and 2018. All patients received prior HD-MTX based chemotherapy (58% (11/19) treated with R-MTX/AraC/Thiotepa, 11% (2/19) treated with R-MTX/AraC and 26% (5/19) treated with R-MTX). All, but 2 patients received R-DeVIC at first progression after 1stline treatment. In 52% (10/19), treatment was discontinued after the first cycle. In 3 patients R-DeVIC was discontinued due to severe infections or renal injury and in 2 patients due to ifosfamide induced neuro-toxicity, as well as progressive disease in 2 patients. 2 patients already achieved complete remission and in one case reasons for discontinuance were not recorded. A 2ndcycle was administered in 47% (9/19) and 3 patients received a 3rdcycles of R-DeVIC. Observed overall response rate after R-DeVIC was 79% (15/19): Five patients with complete and 10 with partial remission, respectively. Three (26%) patients had progressive disease and one patient achieved disease stabilization. Neutropenic fever requiring intravenous antibiotic treatment was the most common adverse event (21% of administered cycles), followed by neurological disturbances, mainly associated with ifosfamide. After a median follow-up of 5 months, 6- month and 12 -month PFS were both 47% (95% CI 24-67); 6 month and 12-month was OS 59% (95% CI 32-78). Conclusions R-DeVIC is a feasible therapeutic salvage option in r/r PCNSL associated with a response rate of 79%. However, substantial toxicity was also observed leading to discontinuation of treatment in about a quarter of patients. Further data will be presented at the meeting. Disclosures Finke: Novartis: Consultancy, Honoraria, Other: travel grants, Research Funding; Medac: Consultancy, Honoraria, Other: travel grants, Research Funding; Neovii: Consultancy, Honoraria, Other: travel grants, Research Funding; Riemser: Consultancy, Honoraria, Research Funding. Illerhaus:Riemser: Consultancy, Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

32

Gokce, Gokcen, OsmanM Ceylan, FatihM Mutlu, HalilI Altinsoy, and Talay Koylu. "Relapsing Devic′s disease in a child." Journal of Pediatric Neurosciences 8, no. 2 (2013): 146. http://dx.doi.org/10.4103/1817-1745.117852.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Bueno Rodríguez, Valentín, María Teresa Hernández Carrero, Miguel Ángel Ponce Villares, and Ángel Luis Guerrero Peral. "Dificultad diagnóstica en una neuromielitis de Devic." Revista de Neurología 28, no. 03 (1999): 341. http://dx.doi.org/10.33588/rn.2803.98403.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Silva, Alexandre R. da, Sonja V. T. Barros, Newra T. Rotta, Ohlweiler Lygia, Isa Stone, and Letícia R. Mello. "Doença de Devic: um relato de caso." Jornal de Pediatria 77, no. 6 (December 2001): 522–24. http://dx.doi.org/10.1590/s0021-75572001000600017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Wuebbolt, Danielle, Vanessa Nguyen, Rohan D’Souza, and Ahraaz Wyne. "Devic syndrome and pregnancy: A case series." Obstetric Medicine 11, no. 4 (April 16, 2018): 171–77. http://dx.doi.org/10.1177/1753495x18758868.

Full text

Abstract:

Background Devic syndrome or neuromyelitis optica is an autoimmune neurological condition characterized by relapsing symptoms of optic neuritis and transverse myelitis. Women with neuromyelitis optica suffer from adverse pregnancy outcomes and high relapse rates during pregnancy and the postpartum period. Methods This case series describes 13 pregnancies in four women with neuromyelitis optica managed at a tertiary hospital in Toronto, Canada. Results In most cases, neurologic symptoms either worsened or developed for the first time during pregnancy or the postpartum period, and often responded to a combination of steroids, immunosuppressant medications, plasma exchange and intravenous immunoglobulin. The 13 pregnancies resulted in two miscarriages, three preterm and eight term births. One fetus whose mother was on gabapentin, prednisone and spironolactone, had congenital malformations (aplastic lung and fused fingers). Conclusions Despite high frequency of relapses in pregnancy and the postpartum period, with multidisciplinary team management, outcomes for women with neuromyelitis optica are encouraging.

APA, Harvard, Vancouver, ISO, and other styles

36

Minagar, Alireza, J. Steven Alexander, Marjorie R. Fowler, Ann C. Long, and Roger E. Kelley. "Devic disease: clinical course, pathophysiology, and management." Pathophysiology 9, no. 1 (October 2002): 33–40. http://dx.doi.org/10.1016/s0928-4680(02)00053-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

de Seze, J. "Histoire de la neuromyélite optique de Devic." Pratique Neurologique - FMC 2, no. 1 (February 2011): 41–44. http://dx.doi.org/10.1016/j.praneu.2010.12.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Fradet, L., and J. Cabane. "La neuromyélite optique de Devic : revue critique." La Revue de Médecine Interne 21 (December 2000): 473. http://dx.doi.org/10.1016/s0248-8663(00)90037-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Maeztu, M. C., R. Villaverde, J. Moreno, J. Cuadrado, R. Lopez-Bernabé, and Luis Garcia. "ID 347 – Facial myokymia in devic disease." Clinical Neurophysiology 127, no. 3 (March 2016): e63. http://dx.doi.org/10.1016/j.clinph.2015.11.210.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Filippi, M., and M. A. Rocca. "MR imaging of Devic?s neuromyelitis optica." Neurological Sciences 25, S4 (November 2004): s371—s373. http://dx.doi.org/10.1007/s10072-004-0344-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Nozaki, I. "Fulminant Devic disease successfully treated by lymphocytapheresis." Journal of Neurology, Neurosurgery & Psychiatry 77, no. 9 (May 18, 2006): 1094–95. http://dx.doi.org/10.1136/jnnp.2005.086306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Antunes, Patrícia Alexandra, Gilbert Bannach, Gilberto Orivaldo Chierice, and Éder Tadeu Gomes Cavalheiro. "Direct and simultaneous spectrophotometric determination of Ni (II) and Co (II) using diethanoldithiocarbamate as complexing agent." Eclética Química Journal 34, no. 2 (January 24, 2018): 07. http://dx.doi.org/10.26850/1678-4618eqj.v34.2.2009.p07-13.

Full text

Abstract:

A direct spectrophotometric method for simultaneous determination of Co(II) and Ni(II), with diethanoldithiocarbamate (DEDC) as complexing agent, is proposed using the maximum absorption at 360 and 638 nm (Co(II)/DEDC) and 390 nm (Ni/DEDC). Adjusting the best metal/ligand ratio, supporting eletrolite, pH, and time of analysis, linear analytical curves from 1.0 10-6-4.0 10-4 for Co(II) in the presence of Ni 1.0 10-6-1.0 10-4 mol L-1 were observed. No further treatment or calculation processes have been necessary. Recoveries in different mixing ratios were of 99%. Interference of Fe(III), Cu(II), Zn(II) and Cd(II), and anions as NO3-, Cl-, ClO4-, citrate and phosphate has been evaluated. The method was applied to natural waters spiked with the cations.

APA, Harvard, Vancouver, ISO, and other styles

43

Antunes, P. A., G. Bannach, G. O. Chierice, and E. T. G. Cavalheiro. "Direct and simultaneous spectrophotometric determination of Ni (II) and Co (II) using diethanoldithiocarbamate as complexing agent." Eclética Química 34, no. 2 (2009): 7–13. http://dx.doi.org/10.1590/s0100-46702009000200001.

Full text

Abstract:

A direct spectrophotometric method for simultaneous determination of Co(II) and Ni(II), with diethanoldithiocarbamate (DEDC) as complexing agent, is proposed using the maximum absorption at 360 and 638 nm (Co(II)/DEDC) and 390 nm (Ni/DEDC). Adjusting the best metal/ligand ratio, supporting eletrolite, pH, and time of analysis, linear analytical curves from 1.0 10-6-4.0 10-4 for Co(II) in the presence of Ni 1.0 10-6-1.0 10-4 mol L-1 were observed. No further treatment or calculation processes have been necessary. Recoveries in different mixing ratios were of 99%. Interference of Fe(III), Cu(II), Zn(II) and Cd(II), and anions as NO3-, Cl-, ClO4-, citrate and phosphate has been evaluated. The method was applied to natural waters spiked with the cations.

APA, Harvard, Vancouver, ISO, and other styles

44

Yamaguchi, Motoko, Ritsuro Suzuki, Masahiko Oguchi, Naoko Asano, Jun Amaki, Takeshi Akiba, Takeshi Maeda, et al. "Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan." Journal of Clinical Oncology 35, no. 1 (January 1, 2017): 32–39. http://dx.doi.org/10.1200/jco.2016.68.1619.

Full text

Abstract:

Purpose To elucidate the management and outcomes of patients with extranodal natural killer/T-cell lymphoma, nasal type (ENKL), who were diagnosed between 2000 and 2013 in Japan. Patients and Methods Data from 358 patients with ENKL diagnosed between 2000 and 2013 from 31 institutes were retrospectively analyzed. Results Patients’ median age was 58 years, and 257 (72%) had localized disease. The most common first-line treatment was radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) (66%) for localized ENKL and L-asparaginase–containing chemotherapy (30%) for advanced ENKL. With a median follow-up of 5.8 years, overall survival (OS) rates at 5 years for localized and advanced ENKL were 68% and 24%, respectively. The prognostic index of natural killer lymphoma was validated in our study, although only 4% of patients with localized ENKL were classified as high risk. With a median follow-up of 5.6 years, OS and progression-free survival at 5 years in the 150 patients who received RT-DeVIC in clinical practice were 72% (95% CI, 63% to 78%) and 61% (95% CI, 52% to 69%), respectively. Toxicities of RT-DeVIC were comparable to those in a previous trial. Multivariate analysis in patients with localized ENKL who received RT-DeVIC identified elevated soluble interleukin-2 receptor as an independent predictive factor for worse OS and progression-free survival (adjusted hazard ratios, 2.28 and 2.46; 95% CI, 1.24 to 4.23 and 1.42 to 4.28; P = .008 and .0014, respectively). Conclusion Favorable OS in response to new treatments was demonstrated in a large number of patients. Improved treatment approaches are needed for localized ENKL exhibiting elevated pretreatment soluble interleukin-2 receptor.

APA, Harvard, Vancouver, ISO, and other styles

45

Cuvier, Victor, Gradel Antoine, Gwenaelle Runavot, Aurélie Ruet, Bruno Brochet, Nicolas Collongues, and Thomas Tourdias. "La neuromyélite optique de Devic à la Réunion." Revue Neurologique 177 (April 2021): S115. http://dx.doi.org/10.1016/j.neurol.2021.02.345.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Kumar, VSiva, BV Devi, CK Kishore, J. V. B. Rao, and B. Vengamma. "Plasma exchange for steroid unresponsive Devic′s disease." Indian Journal of Nephrology 22, no. 6 (2012): 485. http://dx.doi.org/10.4103/0971-4065.106050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Sebastián de la Cruz, Fernando, and Elisa López Dolado. "Neuromielitis óptica de Devic: análisis de siete casos." Revista de Neurología 28, no. 05 (1999): 476. http://dx.doi.org/10.33588/rn.2805.98213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Tashiro, Kunio, Kazunori Ito, Yasunori Maruo, Sanae Homma, Takayoshi Yamada, Naoto Fujiki, and Fumio Moriwaka. "MR Imaging of Spinal Cord in Devic Disease." Journal of Computer Assisted Tomography 11, no. 3 (May 1987): 516–17. http://dx.doi.org/10.1097/00004728-198705000-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Landragin, N., L. Jeanjean, S. Bouly, J. Honnorat, J. de Sèze, G. Castelnovo, and P. Labauge. "Maladie de devic associée à une atrophie médullaire." Revue Neurologique 163, no. 12 (December 2007): 1236–38. http://dx.doi.org/10.1016/s0035-3787(07)78409-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Jouhadi, Z., I. Ouazzani, A. Abid, B. El Moutawakil, M. A. Rafai, and I. Slassi. "Neuromyélite optique de Devic et hépatite virale A." Revue Neurologique 160, no. 12 (December 2004): 1198–202. http://dx.doi.org/10.1016/s0035-3787(04)71167-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!